Home / Health / Vaxcyte Vaccine Excels in Adult Study
Vaxcyte Vaccine Excels in Adult Study
5 Oct
Summary
- Experimental vaccine met main goals in late-stage study.
- Study targeted adults aged 50 and older.
- Vaxcyte shares surged 91% after the announcement.
An experimental pneumococcal vaccine developed by Vaxcyte has achieved success in a late-stage clinical trial. The study focused on adults who are 50 years of age or older, a demographic often at higher risk for pneumococcal diseases.
The vaccine met its main study goals, signaling a potentially significant advancement in preventing pneumococcal infections. This positive outcome led to a notable market reaction, with Vaxcyte's shares jumping by 91% in pre-market trading on Monday, October 5, 2026.
This clinical trial success represents a crucial step forward for Vaxcyte's pipeline. The company continues to work on developing innovative vaccines to address public health needs.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
